GlassScriptPhysician profile
Mary Meaghan Wallace
NPI 1760986558
$4,338.29
in general payments reported to CMS, 2019-2025
28 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,074 · 2022: $1,259 · 2023: $891 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,830.38 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $573.46 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $327.10 | 2021-2023 | Mounjaro, Jardiance, Lyumjev |
| Sanofi-Aventis U.S. LLC | $188.94 | 2021-2022 | |
| Amgen INC. | $177.18 | 2021-2023 | Evenity, Prolia |
| Mannkind Corporation | $130.69 | 2023 | Afrezza |
| Corcept Therapeutics | $127.02 | 2021-2023 | Korlym |
| Insulet Corporation | $106.84 | 2021-2022 | |
| Amarin Pharma, INC. | $89.81 | 2021-2022 | |
| Antares Pharma, INC. | $87.20 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Medtronic, INC. | $86.42 | 2025 | Venaseal |
| Merck Sharp & Dohme LLC | $82.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.29 | 2021-2023 | Jardiance |
| Vivus LLC | $51.12 | 2021 | |
| Zealand Pharma US, INC. | $47.10 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.29 | 2021 | |
| Abbott Laboratories | $38.65 | 2023 | Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $34.71 | 2023 | |
| Organogenesis INC. | $27.51 | 2025 | Apligraf |
| Kyowa Kirin, INC. | $22.80 | 2023 | |
| Amryt Pharma Holdings LTD | $22.35 | 2023 | Mycapssa |
| Bayer Healthcare Pharmaceuticals INC. | $18.90 | 2021 | |
| Averitas Pharma INC. | $16.47 | 2023 | Qutenza |
| Pfizer INC. | $15.33 | 2021 | |
| Vistapharm, INC. | $15.22 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Meaghan Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.